These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 6511242

  • 1. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
    Meguro S, Nagata T, Yokoyama K, Chinen T, Yamazaki H, Kobayashi T, Isogai Y, Ogawa M.
    Invest New Drugs; 1984; 2(4):381-5. PubMed ID: 6511242
    [Abstract] [Full Text] [Related]

  • 2. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
    Meguro S, Nagata T, Yokoyama K, Chinen T, Kobayashi T, Yamazaki H, Kuraishi Y, Ichiba, Abe M, Isogai Y.
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
    [Abstract] [Full Text] [Related]

  • 3. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
    Nishi I, Yokoyama T, Nakao I, Harashima S, Ohashi Y, Kanko T, Saito T.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
    [Abstract] [Full Text] [Related]

  • 4. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
    Takahashi K, Yokoyama M, Takahashi H, Wakui A.
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
    Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H, Hoshi A.
    Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
    [Abstract] [Full Text] [Related]

  • 6. [Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1844-50. PubMed ID: 7184379
    [Abstract] [Full Text] [Related]

  • 7. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
    Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Shibuya M, Shimabukuro Z.
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
    [Abstract] [Full Text] [Related]

  • 8. Mitomycin (Mutamycin).
    Med Lett Drugs Ther; 1975 Jul 18; 17(15):62-3. PubMed ID: 50555
    [No Abstract] [Full Text] [Related]

  • 9. Mitomycin: ten years after approval for marketing.
    Doll DC, Weiss RB, Issell BF.
    J Clin Oncol; 1985 Feb 18; 3(2):276-86. PubMed ID: 3881563
    [Abstract] [Full Text] [Related]

  • 10. [Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa].
    Shimizu E, Saijo N, Shinkai T, Eguchi K, Tominaga K, Nomori H, Sasaki Y, Garcia-Herreros P, Hoshi A.
    Gan To Kagaku Ryoho; 1984 Jun 18; 11(6):1290-5. PubMed ID: 6732255
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with mitomycin C (NSC-26980).
    Whittington RM, Close HP.
    Cancer Chemother Rep; 1970 Jun 18; 54(3):195-8. PubMed ID: 4334088
    [No Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
    Dirix L, Catimel G, Koier I, Provè A, Schrijvers D, Joossens E, De Bruijn E, Ardiet C, Evene E, Dumortier A.
    Anticancer Drugs; 1995 Feb 18; 6(1):53-63. PubMed ID: 7756684
    [Abstract] [Full Text] [Related]

  • 13. Mitomycin-C in breast cancer.
    Hortobagyi GN.
    Semin Oncol; 1985 Dec 18; 12(4 Suppl 6):65-70. PubMed ID: 3936183
    [Abstract] [Full Text] [Related]

  • 14. Effects of mitomycin c (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
    Moore GE, Bross ID, Ausman R, Nadler S, Jones R, Slack N, Rimm AA.
    Cancer Chemother Rep; 1968 Oct 18; 52(6):675-84. PubMed ID: 5753587
    [No Abstract] [Full Text] [Related]

  • 15. [Analysis of factors affecting clinical cancer chemotherapy].
    Wakui A, Taguchi T.
    Gan No Rinsho; 1983 Aug 18; 29(10):1199-204. PubMed ID: 6415312
    [Abstract] [Full Text] [Related]

  • 16. [Anticancer activities of a new mitomycin derivative KW 2149, against human tumors xenografted into nude mice].
    Nishiyama M, Kim R, Saeki T, Takagami S, Kirihara Y, Jinushi K, Toge T, Niimoto M, Hattori T.
    Gan To Kagaku Ryoho; 1988 Nov 18; 15(11):3133-7. PubMed ID: 3142368
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay.
    Kanzawa F, Matsushima Y, Hoshi A, Shimizu E, Saijo N, Miyazawa N.
    Invest New Drugs; 1985 Nov 18; 3(4):341-7. PubMed ID: 3003004
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of mitomycin-C in patients with small cell carcinoma of the lung after failure on combination chemotherapy.
    Joss RA, Obrecht JP, Senn HJ, Alberto P, Sauter C, Cavalli F.
    Eur J Cancer Clin Oncol; 1984 Dec 18; 20(12):1477-9. PubMed ID: 6094197
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
    Tsuruo T, Sudo Y, Asami N, Inaba M, Morimoto M.
    Cancer Chemother Pharmacol; 1990 Dec 18; 27(2):89-93. PubMed ID: 2123421
    [Abstract] [Full Text] [Related]

  • 20. A phase I-II study of continuous 5-day infusion mitomycin-C.
    Yap HY, Valdivieso M, Blumenschein G, Hortobagyi G, Bedikian A.
    Am J Clin Oncol; 1983 Feb 18; 6(1):109-12. PubMed ID: 6404154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.